Recent Updates
Recently added Catalysts
GOSS Positive Sentiment

Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models

Friday, January 30, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the significant anti-fibrotic effects of Seralutinib, supported by evidence from patient-derived models. This finding suggests that Seralutinib may offer promising therapeutic benefits for conditions characterized by fibrosis. The research highlights the potential of this treatment in improving patient outcomes.
Price reaction · baseline $2.42 (2026-01-29 close) · hit pre-market · clean, no other GOSS news in the window
day 0 close · peak
-5.8%
day 1
+2.5%
day 3
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Seralutinib demonstrates significant anti-fibrotic effects.
  • Evidence is derived from patient-derived models.
  • Potential for improved treatment options in fibrosis-related conditions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+53%
120-day peak, hindsight
Typical move
5.9%
average across 2 past catalysts
Cash runway
~4 mo
High dilution risk
Lead asset
GB001
Phase 2 · Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)

Full Press Release Details

Seralutinib shows significant anti-fibrotic effects: Evidence from patient-derived models
• About Overview Team Management Board of Directors Collaboration Contact Locations Contact Form Sponsorship Disclosure
• Seralutinib About Seralutinib PAH PH-ILD Posters & Presentations
• Patients Overview Expanded Access
• Investors Overview News Events & Presentations Events Presentations Filings Governance Overview Committee Composition Management Board of Directors Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage Info FAQs Contact IR Email Alerts
• Careers & Culture Who We Are Open Positions
• Overview
• Team
• Management
• Board of Directors
• Collaboration
• Contact
• Locations
• Contact Form
• Sponsorship Disclosure
• About Seralutinib
• PAH
• PH-ILD
• Posters & Presentations
• Overview
• Expanded Access
• Overview
• News
• Events & Presentations Events Presentations
• Filings
• Governance Overview Committee Composition Management Board of Directors
• Stock Stock Quote & Chart Historical Price Lookup Investment Calculator Analyst Coverage
• Info FAQs Contact IR Email Alerts
• Events
• Presentations
• Overview
• Committee Composition
• Management
• Board of Directors
• Stock Quote & Chart
• Historical Price Lookup
• Investment Calculator
• Analyst Coverage
• FAQs
• Contact IR
• Email Alerts
• Who We Are
• Open Positions

Frequently Asked Questions

What are the effects of Seralutinib?

Seralutinib shows significant anti-fibrotic effects based on research.

What models were used to study Seralutinib?

The evidence for Seralutinib's effects comes from patient-derived models.

What conditions may benefit from Seralutinib?

Seralutinib may improve treatment options for fibrosis-related conditions.

ShareAdd on Google
Tags: GOSS Viatris Investor Conferences Healthcare Seralutinib anti-fibrotic fibrosis patient-derived models
Last updated: Jan 30, 2026

Biotech snapshot

Cash runway
$57M liquidity · $13M/mo burn
~4 mo
High dilution risk
Lead asset
GB001Phase 2
Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) →

Catalyst track record

+53%
best trade around GOSS's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for GOSS.

See every catalyst's timing & PoA →